TY - JOUR
T1 - Prognostic Potential of Electrocardiographic Parameters in Patients with Multiple Myeloma
T2 - A Retrospective Analysis of the Multiple Myeloma Population
AU - Wang, Jie
AU - An, Jiaqi
AU - Tse, Gary
AU - He, Pengcheng
AU - Liu, Haibo
AU - Zhang, Aifeng
AU - Li, Guoliang
AU - Li, Yongxin
AU - Sun, Chaofeng
AU - Yan, Yang
N1 - Publisher Copyright:
© 2020, Springer Healthcare Ltd., part of Springer Nature.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Introduction: Patients with multiple myeloma (MM) can develop cardiac abnormalities, predisposing them to the development of heart failure, arrhythmias, or infarction with poor prognosis. The purpose of this study is to evaluate the prognostic potential of electrocardiographic (ECG) parameters in patients with MM. Methods: This study retrospectively included patients with MM from January 2010 to December 2018 in the First Affiliated Hospital of Xi’an Jiao Tong University. Univariate and multivariate Cox proportional hazard models were conducted to evaluate the relationship between ECG parameters and all-cause mortality in patients with MM. Results: A total of 409 patients were included (mean age 61.3 ± 9.7 years, 59.2% male). The relationship between ECG parameters (including PR interval, voltage, QRS axis, QRS duration, and QTc interval) and all-cause mortality in patients with MM was evaluated. Overall, patients with QTc interval ≥ 400 ms have a significantly higher all-cause mortality compared to those with QTc interval < 400 ms (P < 0.001). When stratified by the International Staging System (ISS), this relationship was true for stages II and III (P < 0.01), but not stage I (P > 0.05). Patients with MM and QRS duration ≥ 120 ms had a higher all-cause mortality compared to those with QRS duration < 120 ms for women (P < 0.01) but not for men (P > 0.05). PR interval, voltage, and QRS axis did not predict mortality. Conclusion: QTc interval was independently associated with all-cause mortality in patients with MM, especially when QTc interval was more than 400 ms in more advanced stages II and III. ECG parameters may provide prognostic potential in patients with MM and aid risk stratification of these patients.
AB - Introduction: Patients with multiple myeloma (MM) can develop cardiac abnormalities, predisposing them to the development of heart failure, arrhythmias, or infarction with poor prognosis. The purpose of this study is to evaluate the prognostic potential of electrocardiographic (ECG) parameters in patients with MM. Methods: This study retrospectively included patients with MM from January 2010 to December 2018 in the First Affiliated Hospital of Xi’an Jiao Tong University. Univariate and multivariate Cox proportional hazard models were conducted to evaluate the relationship between ECG parameters and all-cause mortality in patients with MM. Results: A total of 409 patients were included (mean age 61.3 ± 9.7 years, 59.2% male). The relationship between ECG parameters (including PR interval, voltage, QRS axis, QRS duration, and QTc interval) and all-cause mortality in patients with MM was evaluated. Overall, patients with QTc interval ≥ 400 ms have a significantly higher all-cause mortality compared to those with QTc interval < 400 ms (P < 0.001). When stratified by the International Staging System (ISS), this relationship was true for stages II and III (P < 0.01), but not stage I (P > 0.05). Patients with MM and QRS duration ≥ 120 ms had a higher all-cause mortality compared to those with QRS duration < 120 ms for women (P < 0.01) but not for men (P > 0.05). PR interval, voltage, and QRS axis did not predict mortality. Conclusion: QTc interval was independently associated with all-cause mortality in patients with MM, especially when QTc interval was more than 400 ms in more advanced stages II and III. ECG parameters may provide prognostic potential in patients with MM and aid risk stratification of these patients.
KW - Electrocardiography
KW - Mortality
KW - Multiple myeloma
KW - QTc interval
UR - http://www.scopus.com/inward/record.url?scp=85084120102&partnerID=8YFLogxK
U2 - 10.1007/s12325-020-01343-9
DO - 10.1007/s12325-020-01343-9
M3 - Article
C2 - 32337646
AN - SCOPUS:85084120102
SN - 0741-238X
VL - 37
SP - 2946
EP - 2955
JO - Advances in Therapy
JF - Advances in Therapy
IS - 6
ER -